← Retour au Screener

Sector: Santé
Open in Terminal → AGIOLive chart · Key metrics · News · Smart money

Agios Pharmaceuticals

AGIO Mid Cap

Healthcare · Biotechnology

Mis à jour: Jun 18, 2026, 22:21 UTC

29,81 €
+3.26% aujourd'hui
52W: 19,41 € – 40,14 €
52W Low: 19,41 € Position: 50.2% 52W High: 40,14 €

Price Chart

Indicateurs clés

P/E Ratio
Cours/Bénéfice
Forward P/E
P/E prévisionnel
P/S Ratio
30.76x
Cours/Ventes
EV/EBITDA
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
1,8 Md €
Capitalisation boursière
Croissance du CA
137.7%
Croissance du CA sur un an
Marge bénéficiaire
Marge nette
ROE
-32.81%
Rentabilité des capitaux propres
Beta
0.59
Sensibilité au marché
Positions vendeuses
11.77%
% du flottant vendu à découvert
Volume moyen
1,119,492
Volume quotidien moyen

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
Acheter
8 analysts
Avg. Price Target
35,56 €
+19.29% upside
Target Range
24,43 € – 51,49 €

About the Company

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 539 Exchange: NMS

Agios Pharmaceuticals en bref

Agios Pharmaceuticals (AGIO) is currently trading at 29,81 € with a market capitalization of 1,8 Md €. The 52-week range spans from 19,41 € to 40,14 €; the current price is 25.7% below the yearly high. Year-over-year revenue growth stands at +137.7%.

💰 Dividende

Agios Pharmaceuticals currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

8 analystes évaluent Agios Pharmaceuticals (AGIO) au consensus : Acheter. L'objectif de cours moyen est de 35,56 €, soit un potentiel de +19.29% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 24,43 € à 51,49 €.

Agios Pharmaceuticals : la thèse d'investissement en détail

Agios Pharmaceuticals (AGIO) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 137.7% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. Wall Street consensus sits at Buy with an average price target implying roughly 19.29% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Short interest sits at 11.77% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Thèse d'investissement : forces et faiblesses

Points forts
  • Forte croissance du CA de 137.7% sur un an
  • Consensus des analystes : Buy
  • Bilan solide avec faible endettement (D/E 3.22)
Points faibles
  • Positions vendeuses élevées (11.77%)
  • Free cash flow négatif

Aperçu technique

MM 50 jours
25,33 €
+17.71% vs. cours
MM 200 jours
27,72 €
+7.56% vs. cours
Sous le plus haut 52s
−25.7%
40,14 €
Au-dessus du plus bas 52s
+53.6%
19,41 €

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

Risque de marché (Bêta)
0.59 · Défensive
Évolue moins que le marché global
Positions vendeuses
11.77% · Élevé
% du flottant vendu à découvert
Dette/Capitaux propres
3.22 · Faible
Dette totale / capitaux propres

The data points to relatively defensive market behavior, elevated short interest (11.77%).

Trading Data

50-Day MA: 25,33 €
200-Day MA: 27,72 €
Volume: 1,783,524
Avg. Volume: 1,119,492
Short Ratio: 7.14
P/B Ratio: 1.83x
Debt/Equity: 3.22x
Free Cash Flow: -233 198 226 €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy Agios Pharmaceuticals?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut